Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STIMATE vs DIAPID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Desmopressin acetate is a synthetic analog of the natural pituitary hormone 8-arginine vasopressin (ADH). It acts as a V2 receptor agonist in the renal collecting ducts, increasing water permeability and promoting water reabsorption, thereby reducing urine output. It also increases plasma levels of von Willebrand factor and factor VIII via V2 receptor stimulation on endothelial cells.
Diapid (lypressin) is a synthetic analog of vasopressin that acts as an antidiuretic by increasing water reabsorption in the renal collecting ducts via V2 receptor activation. It also has mild vasopressor activity via V1 receptor stimulation.
Central diabetes insipidus,Primary nocturnal enuresis,Hemophilia A with factor VIII levels >5%,von Willebrand disease (type 1)
Diabetes insipidus (central),Nocturnal enuresis (off-label)
Intranasal: 1 spray (1.5 mg) into one nostril, 1 hour prior to voiding or on awakening for bedwetting; maximum 2 sprays per day.
Intravenous bolus of 20 mg followed by 20-40 mg every 2-4 hours as needed. Maximum single dose: 80 mg.
Terminal elimination half-life is approximately 3-4 hours in healthy adults, but may be prolonged in patients with renal impairment or in older adults.
Terminal elimination half-life is 1.5-3 hours; clinically significant in patients with renal impairment, requiring dose adjustment
Not extensively metabolized; primarily excreted unchanged in urine. A small fraction may be metabolized by liver or kidney peptidases.
Lypressin is rapidly metabolized by peptidases in the liver and kidneys, with a half-life of approximately 15 minutes.
Desmopressin is primarily excreted renally, with approximately 60-70% of the dose recovered unchanged in urine within 24 hours. The remaining fraction is metabolized hepatically and eliminated via feces.
Primarily renal excretion as unchanged drug (80-90%); minor biliary/fecal elimination (<10%)
Desmopressin exhibits low protein binding, approximately 1-2%, primarily to albumin.
20-30% bound to plasma proteins
Volume of distribution is 0.2-0.4 L/kg, indicating distribution primarily in extracellular fluid.
0.6-0.8 L/kg; distributes primarily in extracellular fluid
Intranasal: 10-20%; Oral: 5-10% due to extensive first-pass metabolism.
100% by intravenous route; Not bioavailable orally
No specific adjustment; caution in severe impairment (e GFR <15 m L/min).
No adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce dose by 50%. For GFR <10 m L/min: avoid use.
No specific adjustment; limited data in Child-Pugh C; use cautiously.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Children ≥6 years: same as adult; intranasal 1 spray (1.5 mg) 1 hour before bedtime. Do not exceed 2 sprays per day.
0.2 mg/kg intravenously, repeat every 2 hours as needed. Maximum dose: 10 mg.
Use caution due to risk of hyponatremia and hypertension; start at lowest effective dose.
Initial dose of 10 mg intravenously, titrate cautiously due to increased sensitivity. Maximum single dose: 40 mg.
No FDA black box warning exists for STIMATE.
None.
Hyponatremia and fluid overload with water intoxication,Seizures due to hyponatremia,Thrombotic events (in patients with predisposing factors),Caution in patients with cystic fibrosis, coronary artery disease, or hypertension,Risk of arterial or venous thrombosis, especially with desmopressin treatment for bleeding disorders,Elderly patients at increased risk of hyponatremia
Monitor fluid and electrolyte balance to avoid water intoxication and hyponatremia.,Use with caution in patients with coronary artery disease, hypertension, or renal impairment.,May cause anaphylaxis or hypersensitivity reactions.
Hypersensitivity to desmopressin or any component,Moderate to severe renal impairment (Cr Cl <50 m L/min),Hyponatremia or history of hyponatremia,Known platelet-type von Willebrand disease (pseudo-von Willebrand disease),Unstable angina, decompensated heart failure, or severe coronary artery disease
Hypersensitivity to lypressin or any component,Severe renal impairment (anuria),Chronic nephritis with nitrogen retention
No specific food interactions. However, avoid excessive fluid intake (more than needed to satisfy thirst) while taking STIMATE to reduce risk of water intoxication and hyponatremia. For patients with nocturnal enuresis, restrict fluids 1 hour before bedtime.
No significant food interactions. However, avoid excessive water intake and alcohol, which can affect ADH secretion.
Pregnancy Category X. Desmopressin (STIMATE) is contraindicated in pregnancy due to risk of uterine contractions and potential fetal harm. First trimester: No adequate studies; theoretical risk of teratogenicity. Second trimester: Avoid due to risk of preterm labor. Third trimester: May induce premature labor; use only if clearly needed for diabetes insipidus.
Diapide is contraindicated in pregnancy due to known teratogenic effects. First trimester exposure is associated with increased risk of congenital malformations, particularly cardiovascular and neural tube defects. Second and third trimester exposure may cause fetal hyperinsulinemia, macrosomia, and neonatal hypoglycemia.
Desmopressin is excreted in breast milk in low amounts; M/P ratio not established. No adverse effects reported in infants. Use with caution, especially in nursing mothers with preeclampsia due to potential for water intoxication.
Excretion into breast milk is unknown; however, due to potential for adverse effects in the nursing infant (e.g., hypoglycemia), breastfeeding is not recommended during therapy. M/P ratio: not determined.
Increased plasma volume and enhanced renal clearance in pregnancy may reduce desmopressin concentrations; dose adjustments may be required. Monitor clinical response and adjust dose based on urine output and plasma sodium. No standard dose adjustment; individualize therapy.
No safe dose established in pregnancy. If use is unavoidable during pregnancy, dose adjustment is not recommended due to teratogenicity; alternative therapy should be employed.
STIMATE (desmopressin acetate) is a synthetic analog of vasopressin used for diabetes insipidus and nocturnal enuresis. Monitor for hyponatremia, especially in patients with increased fluid intake, elderly, or those on medications that increase ADH (e.g., SSRIs, NSAIDs). Use with caution in patients with renal impairment, cardiovascular disease, or cystic fibrosis. Avoid use in patients with primary polydipsia or uncontrolled hypertension. For nocturnal enuresis, limit fluid intake 1 hour before dose. Start at lowest effective dose and titrate. Can be administered intranasally, orally, or intravenously. Intranasal route is not recommended for infants due to variable absorption.
Diapid (desmopressin) is used for central diabetes insipidus and nocturnal enuresis. Monitor for hyponatremia, especially in elderly or patients with fluid/electrolyte imbalance. Avoid overhydration. Intranasal formulation may cause rhinitis or epistaxis.
Take STIMATE exactly as prescribed; do not increase dose or frequency without consulting your doctor.,For nocturnal enuresis: avoid drinking fluids 1 hour before bedtime and use the bathroom before going to sleep.,Report signs of hyponatremia: headache, nausea, vomiting, confusion, muscle cramps, weakness, or seizures.,Do not use STIMATE if you have allergies to desmopressin or any ingredient in the formulation.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease, heart disease, or cystic fibrosis.,Store STIMATE at room temperature away from moisture and heat; do not freeze.,For intranasal spray: prime the pump before first use and when not used for 7 days. Blow nose gently before use and do not sniff deeply after spraying.,Do not share your medication with others.
Use exactly as prescribed; do not exceed dose to avoid water intoxication.,Limit fluid intake to prevent hyponatremia (symptoms: headache, nausea, confusion).,For intranasal spray, gentle priming and alternating nostrils each dose.,Report signs of low sodium: severe headache, vomiting, muscle cramps, drowsiness.
"Lumacaftor, a component of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector therapy, is a strong inducer of cytochrome P450 (CYP) 3A4 enzymes. Concurrent administration with norgestimate, a progestin component of oral contraceptives that is metabolized primarily by CYP3A4, can significantly reduce norgestimate plasma concentrations. This reduction may diminish the contraceptive efficacy and potentially lead to unintended pregnancy, as well as reduced therapeutic effects for other indications of norgestimate."
"Norgestimate, a progestin component of oral contraceptives, may induce the activity of UDP-glucuronosyltransferases (UGTs), particularly UGT1A1 and UGT2B7, which are involved in the glucuronidation and clearance of miglustat. This enzyme induction can decrease miglustat plasma concentrations, potentially reducing its therapeutic efficacy in treating Gaucher disease or Niemann-Pick type C disease. The clinical outcome could be diminished disease control, requiring dose adjustments or alternative therapy."
"Oxcarbazepine, a potent inducer of cytochrome P450 3A4 (CYP3A4) and uridine diphosphate glucuronosyltransferases (UGTs), significantly decreases the serum concentration of norgestimate by enhancing its hepatic metabolism. This metabolic induction converts norgestimate to less active metabolites, reducing its contraceptive efficacy. Clinically, this interaction may lead to unintended pregnancy in women using hormonal contraceptives containing norgestimate, as well as potential breakthrough bleeding or irregular menstrual cycles."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STIMATE vs DIAPID, answered by our medical review team.
STIMATE is a Antidiuretic Hormone Analog that works by Desmopressin acetate is a synthetic analog of the natural pituitary hormone 8-arginine vasopressin (ADH). It acts as a V2 receptor agonist in the renal collecting ducts, increasing water permeability and promoting water reabsorption, thereby reducing urine output. It also increases plasma levels of von Willebrand factor and factor VIII via V2 receptor stimulation on endothelial cells.. DIAPID is a Antidiuretic Hormone Analog that works by Diapid (lypressin) is a synthetic analog of vasopressin that acts as an antidiuretic by increasing water reabsorption in the renal collecting ducts via V2 receptor activation. It also has mild vasopressor activity via V1 receptor stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STIMATE and DIAPID depend on the specific clinical indication. These are both Antidiuretic Hormone Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STIMATE is: Intranasal: 1 spray (1.5 mg) into one nostril, 1 hour prior to voiding or on awakening for bedwetting; maximum 2 sprays per day.. The standard adult dose of DIAPID is: Intravenous bolus of 20 mg followed by 20-40 mg every 2-4 hours as needed. Maximum single dose: 80 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STIMATE and DIAPID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STIMATE is classified as Category C. Pregnancy Category X. Desmopressin (STIMATE) is contraindicated in pregnancy due to risk of uterine contractions and potential fetal harm. First trimester: No adequate studies; the. DIAPID is classified as Category C. Diapide is contraindicated in pregnancy due to known teratogenic effects. First trimester exposure is associated with increased risk of congenital malformations, particularly cardi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.